Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Wells Fargo & Co

Wells Fargo & Co reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note released on Wednesday morning, AnalystRatings.com reports.

A number of other equities analysts also recently weighed in on the stock. TheStreet raised shares of Jazz Pharmaceuticals from a c+ rating to a b- rating in a research note on Wednesday, July 24th. BMO Capital Markets set a $208.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, July 3rd. HC Wainwright restated a hold rating and issued a $147.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Oppenheimer set a $176.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Monday, July 8th. Finally, BidaskClub upgraded shares of Jazz Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of Buy and a consensus target price of $176.53.

Shares of JAZZ stock traded down $3.44 during trading hours on Wednesday, hitting $129.91. The company’s stock had a trading volume of 12,002 shares, compared to its average volume of 415,347. The stock has a fifty day moving average of $138.34. The firm has a market capitalization of $7.36 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 1.13 and a beta of 1.14. Jazz Pharmaceuticals has a twelve month low of $113.52 and a twelve month high of $176.73. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58.



Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.16 by $0.49. The business had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.49 earnings per share. On average, analysts anticipate that Jazz Pharmaceuticals will post 13.41 earnings per share for the current fiscal year.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $135.65, for a total value of $98,481.90. Following the completion of the transaction, the director now directly owns 9,574 shares in the company, valued at $1,298,713.10. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Renaissance Technologies LLC increased its stake in Jazz Pharmaceuticals by 28.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after acquiring an additional 562,700 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Jazz Pharmaceuticals by 16.7% in the first quarter. JPMorgan Chase & Co. now owns 2,262,159 shares of the specialty pharmaceutical company’s stock valued at $323,376,000 after buying an additional 324,080 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 4,979.1% in the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock valued at $274,324,000 after buying an additional 1,886,384 shares during the last quarter. LSV Asset Management raised its holdings in shares of Jazz Pharmaceuticals by 12.5% in the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock valued at $160,682,000 after buying an additional 125,470 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 46.9% in the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock valued at $147,496,000 after buying an additional 337,396 shares during the last quarter. Hedge funds and other institutional investors own 89.59% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What is the yield curve?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.